Company research / ALXO

ALX Oncology Holdings Inc (ALXO)

SEC name ALX ONCOLOGY HOLDINGS INC · CIK 0001810182 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

Key ratios (year ended 2025-12-31)

-391.4%
Return on year-end equity

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-10-15

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30
2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Revenuen/an/an/an/a$0$0$1.18M$4.80M$2.07M
R&D Expense$61.83M$77.00M$116.37M$141.79M$98.40M$60.17M$28.96M$16.31M$11.27M
Operating Income-$82.55M-$104.02M-$142.47M-$170.28M-$127.44M-$83.56M-$43.66M-$19.18M-$13.68M
Depreciation & Amortization$540.0K$706.0K$872.0K$836.0K$342.0K$51.0K$202.0K$429.0K$431.0K
EBITDA-$82.01M-$103.31M-$141.59M-$169.44M-$127.09M-$83.50M-$43.46M-$18.75M-$13.25M
Net Income-$80.89M-$101.69M-$134.85M-$160.81M-$123.48M-$83.46M-$45.74M-$19.24M-$13.73M
EPS (Diluted)n/a-$1.90-$2.58-$3.74-$3.03-$2.07-$2.76n/an/a
Total Assets$160.82M$59.05M$147.78M$242.55M$306.49M$380.18M$436.05M$10.68Mn/a
Total Liabilities$24.63M$33.06M$34.16M$52.84M$43.02M$17.13M$6.21M$10.95Mn/a
Long-Term Debt$10.20M$10.16M$10.60M$10.60M$10.60Mn/an/an/an/a
Shareholders' Equity$136.19M$25.98M$113.62M$189.71M$263.46M$363.05M$429.85M-$70.64M-$51.78M
Cash & Equivalents$22.69M$16.37M$17.57M$22.41M$48.82M$363.67M$434.22M$9.02Mn/a
Operating Cash Flow-$70.78M-$84.14M-$121.91M-$130.36M-$89.22M-$68.10M-$38.29M-$14.25M-$13.19M
Capital Expenditures$172.0K$212.0K$447.0K$1.27M$1.43M$666.0K$31.0K$353.0K$653.0K
Free Cash Flow-$70.95M-$84.35M-$122.36M-$131.64M-$90.65M-$68.77M-$38.32M-$14.60M-$13.84M
Share Repurchasesn/an/an/an/an/an/an/an/a$6.0K
Shares Outstanding138.22M54.39M53.05M49.95M40.86M40.59M39.84M3.17Mn/a
Weighted Average Diluted Sharesn/a53.66M52.17M42.99M40.70M40.31M18.49Mn/an/a
EPS (Basic)n/a-$1.90-$2.58-$3.74-$3.03-$2.07-$2.76n/an/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView